Hormone Therapy May Help Improve Menopause Brain Fog, Mood Changes - Healthline
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Share on PinterestRecent research has shown that hormone therapy may help improve brain fog and mood changes associated with menopause. elenaleonova · E+/GettyHormone therapy may affect changes in the brain that occur during menopause. A recent study has shown that hormone therapy may help improve “brain fog” symptoms during menopause. Another study found that hormone therapy may improve mood changes that are often associated with menopause. Other research has alleviated long-standing concerns over a possible link between menopause hormone therapy and dementia. Menopause hormone therapy (MHT), also known as hormone replacement therapy (HRT), helps manage various menopause symptoms. However, recent research has found that MHT may also help improve mental symptoms like “brain fog” and mood changes. Other research also found that MHT does not affect dementia risk. This research followed the FDA’s removal of the black box warning on these products, which suggested they may increase the risk. Together, these studies show that MHT may help people experiencing menopause in ways not previously realized and that it is generally safe to use.
This article is an excerpt. To read the full content, visit the original source. Healthline
Related articles
Bioengineer.org | Viral blips during HIV therapy are common and rarely signal treatment failure, Swedish study finds - European AIDS Treatment Group
Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.
European Medical Journal | HIV linked to early signs of heart dysfunction - European AIDS Treatment Group
European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.
Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patients - Medical Xpress
Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.
0 comments
No comments yet. Be the first to share your thoughts!